CBIO
Crescent Biopharma
CBIO
CBIO
89 hedge funds and large institutions have $145M invested in Crescent Biopharma in 2020 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 29 increasing their positions, 22 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
0.03% less ownership
Funds ownership: 0.84% → 0.81% (-0.03%)
46% less call options, than puts
Call options by funds: $387K | Put options by funds: $714K
Holders
89
Holding in Top 10
–
Calls
$387K
Puts
$714K
Top Buyers
| 1 | +$8.65M | |
| 2 | +$3.38M | |
| 3 | +$3.06M | |
| 4 |
CCM
CAAS Capital Management
New York
|
+$1.88M |
| 5 |
Two Sigma Investments
New York
|
+$1.76M |
Top Sellers
| 1 | -$11.4M | |
| 2 | -$11.3M | |
| 3 | -$1.2M | |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$1.13M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$896K |